Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial
European Journal of Neurology · 2026-04 · 33 (4)
DOI: 10.1111/ene.70580 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, online erschienen am 30.03.2026. Verfasst von Julian D Gillmore und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, University College London, London, UK. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin, Polyneuropathies. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
This exploratory analysis of the NEURO‐TTRansform Phase 3 trial evaluated the efficacy of eplontersen in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy by genetic variant.
Methods
Changes from baseline in NEURO‐TTRansform primary endpoints serum transthyretin (TTR) at Week 65, modified Neuropathy Impairment Score+7 (mNIS+7) composite score, and Norfolk Quality of Life‐Diabetic Neuropathy (Norfolk QoL‐DN) total score at Week 66 were evaluated in patients with early‐onset (aged < 50 years) and late‐onset (aged ≥ 50 years) Val30Met (p.Val50Met) or non‐Val30Met ATTRv amyloidosis with polyneuropathy. Secondary endpoints from NEURO‐TTRansform were also evaluated by genetic variant.
Results
In total, 144 patients with early‐onset ( n = 54) or late‐onset ( n = 31) Val30Met or non‐Val30Met ( n = 59), ATTRv amyloidosis with polyneuropathy were randomized to eplontersen. A further 60 patients from NEURO‐TTR with early‐onset ( n = 16) or late‐onset ( n = 17) Val30Met or non‐Val30Met ( n = 27), served as a historical placebo group. The mean percentage difference (95% confidence interval) in serum TTR was −79.9 (−87.8, −72.0), −85.0 (−93.3, −76.6), and −70.6 (−77.7, −63.5) with eplontersen versus placebo in the early‐ and late‐onset Val30Met, and non‐Val30Met groups, respectively. Across subgroups, the change from baseline to Week 66 in mNIS+7 composite score was generally well maintained, and the Norfolk QoL‐DN total score improved with eplontersen versus worsening with placebo. The Polyneuropathy Disability score was maintained in most patients. From baseline to Week 65, the modified body mass index was maintained with eplontersen compared to a marked reduction (worsening) for placebo.
Conclusions
Findings were suggestive of consistent benefits in reducing neuropathy impairment and improving QoL with eplontersen versus historical placebo, across TTR variants. Trial Registration ClinicalTrials.gov: NCT04136184, NCT01737398
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Amyloidosis Centre, University College London, London, UK.
- Neurology Department, CHU de Bicêtre, AP-HP, Université Paris-Saclay, Le-Kremlin-Bicêtre, France.
- Amyloidosis Center and Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
- Oregon Health & Science University, Portland, Oregon, USA.
- Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
- BioPharmaceuticals Business Unit, AstraZeneca, Gothenburg, Sweden.
ORCID-Profile: Julian D Gillmore, David Adams, Markus Weiler, Morie Gertz
Förderung
- AstraZeneca
Zitieren
APA
Gillmore, J. D., Adams, D., Weiler, M., Masri, A., Obici, L., Nåtman, J., Kwoh, T. J., Reicher, B., Revkin, J., Cruz, M. W., Gertz, M., & Chao, C. C. (2026). Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70580
Vancouver
Gillmore JD, Adams D, Weiler M, Masri A, Obici L, Nåtman J, et al. Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70580
BibTeX
@article{Gillmore2026,
author = {Gillmore, Julian D and Adams, David and Weiler, Markus and Masri, Ahmad and Obici, Laura and Nåtman, Jonatan and Kwoh, T Jesse and Reicher, Barry and Revkin, James and Cruz, Márcia Waddington and Gertz, Morie and Chao, Chi-Chao},
title = {Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {4},
doi = {10.1111/ene.70580}
}
EUVIMED